{
    "nct_id": "NCT04150614",
    "official_title": "BMT-08: A Comparative Effectiveness Study of the Efficacy and Safety of Transdermal Granisetron to Ondansetron in the Prevention of Nausea and Vomiting in Patients Undergoing Preparative Chemotherapy and Hematopoietic Stem Cell Transplantation",
    "inclusion_criteria": "* Age 18-75 years at time of enrollment receiving either a preparative regimen and either an autologous or allogeneic stem cell transplant.\n* No vomiting ≤ 24 hours prior to registration\n* No treatment with an antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone for ≤ 30 days' prior registration or planned during protocol therapy. No patients will be removed from these treatments for study enrollment purposes.\n* No chronic phenothiazine administration as an antipsychotic agent (patients may receive prochlorperazine and other phenothiazines as rescue antiemetic therapy). No patients will be removed from these treatments for study enrollment purposes.\n* No known hypersensitivity to granisetron\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Concurrent use of amifostine\n* Known hypersensitivity to granisetron patch or ondansetron\n* Patients with a history of long QT syndrome or Torsade de Pointes",
    "miscellaneous_criteria": ""
}